US20060014930A1 - Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses - Google Patents
Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses Download PDFInfo
- Publication number
- US20060014930A1 US20060014930A1 US10/763,286 US76328604A US2006014930A1 US 20060014930 A1 US20060014930 A1 US 20060014930A1 US 76328604 A US76328604 A US 76328604A US 2006014930 A1 US2006014930 A1 US 2006014930A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- seq
- sequence
- protein
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 266
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title claims abstract description 41
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 title description 16
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 title description 16
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract description 41
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims abstract description 39
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims abstract description 39
- 230000003612 virological effect Effects 0.000 claims abstract description 39
- 108010025076 Holoenzymes Proteins 0.000 claims abstract description 29
- 238000000338 in vitro Methods 0.000 claims abstract description 13
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 12
- 208000036142 Viral infection Diseases 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 102000004169 proteins and genes Human genes 0.000 claims description 86
- 210000004027 cell Anatomy 0.000 claims description 57
- 101710149136 Protein Vpr Proteins 0.000 claims description 36
- 230000003071 parasitic effect Effects 0.000 claims description 29
- 230000001413 cellular effect Effects 0.000 claims description 25
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 24
- 102000006478 Protein Phosphatase 2 Human genes 0.000 claims description 21
- 108010058956 Protein Phosphatase 2 Proteins 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 19
- 230000003993 interaction Effects 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 230000006907 apoptotic process Effects 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 13
- 244000045947 parasite Species 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 241000223779 Theileria parva Species 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 108010026424 tau Proteins Proteins 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 4
- 241000222722 Leishmania <genus> Species 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 claims description 2
- 102000009410 Chemokine receptor Human genes 0.000 claims description 2
- 108050000299 Chemokine receptor Proteins 0.000 claims description 2
- 101710202709 Middle T antigen Proteins 0.000 claims description 2
- 101150048267 PAK3 gene Proteins 0.000 claims description 2
- 101150038791 Pak1 gene Proteins 0.000 claims description 2
- 102100036782 Serine/threonine-protein phosphatase 2A activator Human genes 0.000 claims description 2
- 101710196539 Serine/threonine-protein phosphatase 2A activator Proteins 0.000 claims description 2
- -1 Tap42/alpha 4 Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 229920000327 poly(triphenylamine) polymer Polymers 0.000 claims description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 71
- 230000000694 effects Effects 0.000 description 19
- 230000035899 viability Effects 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 11
- 101150029620 PP2A1 gene Proteins 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108700018662 Human immunodeficiency virus 1 vpr Proteins 0.000 description 6
- 241000223777 Theileria Species 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000000149 penetrating effect Effects 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 241000223960 Plasmodium falciparum Species 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940048914 protamine Drugs 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000013498 tau Proteins Human genes 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 3
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000023856 peptide binding proteins Human genes 0.000 description 2
- 108091008399 peptide binding proteins Proteins 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014723 transformation of host cell by virus Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000006490 viral transcription Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DAZBILQQVFBVPE-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2r)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 DAZBILQQVFBVPE-XKKUQSFHSA-N 0.000 description 1
- BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 241001647367 Chlamydia muridarum Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N I Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 101150026829 JUNB gene Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- 102100021538 Protein kinase C zeta type Human genes 0.000 description 1
- 101710204571 Protein phosphatase PP2A regulatory subunit A Proteins 0.000 description 1
- 101710204573 Protein phosphatase PP2A regulatory subunit B Proteins 0.000 description 1
- 101710185500 Small t antigen Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100030246 Transcription factor Sp1 Human genes 0.000 description 1
- 101710085924 Transcription factor Sp1 Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108700015995 adenovirus E4orf4 Proteins 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 108010011990 peptide 74 Proteins 0.000 description 1
- YYCZLGUOLIWZAW-GVETXGJZSA-N peptide 75 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C1=CC=CC=C1 YYCZLGUOLIWZAW-GVETXGJZSA-N 0.000 description 1
- 108010012038 peptide 78 Proteins 0.000 description 1
- 229940125863 peptide 78 Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 108010050991 protein kinase C zeta Proteins 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000006394 virus-host interaction Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to novel synthetic or natural peptides, in particular for use in treating viral or parasitic infections or in the treatment of tumors, said peptides being less than 30 amino acids in size, preferably less than 20 amino acids, in particular 15 to 20 amino acids, and characterized in that in vitro, they specifically bind a type 2A protein phosphatase holoenzyme or one of its subunits.
- the invention also relates to a method for identifying said peptides, and to their uses.
- Cell physiology is partially controlled by modulating protein phosphorylation.
- the phosphorylation state of cell proteins depends on the antagonist action of protein kinases which phosphorylates them and protein phosphatases which dephosphorylate them.
- Protein phosphatases are divided into two principal groups: tyrosine phosphatases and serine/threonine phosphatases. Serine/threonine phosphatases are classified into two categories which depend on the specificicity of their substrate and their sensitivity to certain inhibitors, namely type 1 phosphatases (PP1) and type 2 phosphatases (PP2). Type 2 phosphatases are themselves divided into different classes, including phosphatase 2A (PP2A), phosphatase 2B or calcineurine the activity of which is regulated by calcium, and phosphatase 2C (PP2C) the activity of which is regulated by magnesium.
- P2A phosphatase 2A
- phosphatase 2B phosphatase 2B or calcineurine the activity of which is regulated by calcium
- P2C phosphatase 2C
- type 2A phosphatases are highly conserved during evolution and are potentially involved in regulating many biological processes.
- PP2A enzymes have been clearly involved in regulating transcription, control of the cell cycle or viral transformation. Further, PP2As are targeted by different viral or parasitic proteins, suggesting a role for PP2As in, host-pathogen interactions.
- PP2As are oligomeric complexes (holoenzymes) each comprising a catalytic subunit (C) and one or two regulating subunits (A) and (B).
- the structure of subunit (A) consists of 15 imperfect repeats of a conserved amino acid sequence of 38 to 40 amino acids, certain of which interact with subunits (B) and (C).
- Subunits (A) and (C), conserved during evolution, constitute the base structure of the enzyme and are expressed constitutively.
- subunits (B) constitute a family of regulating proteins not connected via a common structure and expressed differentially (Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 1989; 58: 453-508).
- Protein phosphatase 2As exist in vivo in two classes with different forms: a dimeric form (AC) and a trimeric form (ABC). Subunits (B) regulate phosphatase activity and specificity towards the substrate. The existence of multiple forms of PP2A is correlated with the distinct and varied functions of PP2A in vivo.
- parainfluenza virus incorporates the protein PKC ⁇ , a protein of cellular origin under the control of PP2A, into its viral particle. This can perturb the phosphoylation of host proteins and facilitate its own replication (De B P, Gupta S, Barnejee A K. Cellular protein kinase C ⁇ regulates human parainfluenza virus type 3 replication. Proc. Natl Acad Sci USA 1995; 92: 5204-8).
- DNA viruses with transforming power such as papovae or adenoviruses, as well as certain retroviruses such as the type-1 human immunodeficiency virus (HIV-1), code for proteins which interact directly with certain host PP2As. All of those viruses comprise proteins which, although structurally different, interact with certain holoenzymes and modify phosphatase activity.
- HIV-1 human immunodeficiency virus
- E4orf4 protein of adenoviruses binds to a heterotrimeric PP2A and more precisely to a regulating subunit (B), which causes a reduction in the transcription of JunB in the infected cell. That effect could play an important role during viral infection by regulating the apoptotic response of infected cells.
- B regulating subunit
- the interaction of E4orf4 with PP2A induces apoptosis in transformed cells in a p53-independent manner (Shtrichman R et al, Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells. J Virol 1998; 72: 2975-82).
- Tumor-generating viruses of the Papovae family including SV40 and polyoma virus, induce cell transformation. It has been shown that PP2A interacts with the “small T” antigen of SV40 or polyoma and with the transforming “middle T” protein of polyoma. Those interactions of viral proteins with PP2A have been clearly involved in viral transformation. Finally, transcriptional regulation, a process normally carried out in the cell by different factors specifically fixing to promoter regulating sequences, probably represents the most important mechanism involved in the control of viral expression by PP2A.
- PP2A is a negative regulator for numerous transcription factors involved in particular in the processes of cell growth and proliferation, including AP1/SRE, NF- ⁇ B, Sp1 and CREB (Waszinski, B E, Wheat W H, Jaspers S, Peruski L F, J R Lickier R L, Johnson G L, and Klemm D J, Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol Cell Biol 1993 13, 2822-34). Viral regulation of those transcription factors would permit modulation of viral transcription.
- Vpr The viral protein of HIV-1, Vpr, interacts in vitro with PP2A and stimulates the catalytic activity of PP2A (Tung L et al, Direct activation of protein phosphatase 2A0 by HIV-1 encoded protein complex Ncp7: vpr. FEBS Lett 1997; 401: 197-201). Vpr can induce the G2 stoppage of infected cells by inhibiting the activation of the p34cdc2-cycline B complex. Further, Vpr interacts with the transcription factor Sp1 and is a weak trans-activator for transcription of Sp1 dependent HIV-1.
- the Vpr protein of HIV-1 which is incorporated into the virion, should be involved in vivo in the initiation of viral transcription, a step that is clearly essential for regulating the expression of the Tat transcription factor (a major regulator of transcription encoded by the HIV-1 virus).
- Serine/threonine phosphatases have recently been studied in Theileria parva, another protozoan close to P. falciparum, a cattle parasite. Monocyte and leukocyte host cells infected by the parasite are transformed, resulting in leukemia in the animal. Purified parasites of cells infected with Theileria express a protein kinase CK2 ⁇ . Now, the subunit CK2 ⁇ should interact with PP2A to positively modulate its activity (Hériché H, et al, Regulation of protein phosphatase 2A by direct interaction with casein kinase 2 ⁇ . Science 1997; 276-952-5).
- modulation of PP2A via expression of the CK2 ⁇ subunit could be the basis of blockage of two signal routes in the parasitised cell, that of MAP-kinases (Cvicpied M et al. Theileria transformation of bovine leukocytes: a parasite model for the study of lymphoproliferation. Res Immunol 1996; 147: 127-38) and that of protein kinase B (Akt) (M Baumgartner, M Cvicpied, M F Moreau, A Garcia, G Langsley. Constitutive PI3-K activity is essential for proliferation, but not survival, of Theileria parva —transformed B cells. Cellular Microbiol (2000) 2, 329-339).
- the identification of peptides interacting with PP2A should allow novel drugs to be developed that can block, by competitive inhibition, the cell mechanisms induced by viral or parasitic proteins via their interaction with PP2A and in particular mechanisms of infection, pathogen proliferation and cell transformation.
- the invention pertains to means for identifying peptides of reduced size, binding a PP2A holoenzyme or one of its subunits.
- reduced size peptides In contrast to native proteins or polypeptide domains of large size, reduced size peptides have the advantage of being readily synthesized, either chemically or in cell systems, in high yields and cheaply.
- the peptides of the invention are also more stable and more readily transferred into the cytoplasm or into the nucleus of cells using appropriate vectors, with a view to therapeutic use.
- the invention derives from the demonstration that it is possible to identify peptides with a size of less than 30 amino acids, and in particular peptides less than 20 amino acids in size, interacting with a PP2A holoenzyme or one of its subunits.
- the inventors have identified peptides less than 20 amino acids in size interacting in vitro with purified PP2A holoenzyme or one of its subunits, said peptides being derived from the Vpr protein of HIV-1 or the CK2 ⁇ protein of the T parva parasite. Antagonists derived from these peptides and selected because they inhibit the interaction of viral or parasititc proteins with a particular PP2A holoenzyme could then constitute novel anti-tumoural, antiviral or antiparasitic agents.
- the invention concerns a method for identifying a peptide the sequence of which is derived from a viral, parasitic or cellular protein, said peptide specifically binding a type, 2A protein phosphatase holoenzyme or one of its subunits, said method comprising the steps consisting of:
- step a different peptides are deposited on a solid support in defined positions (“spot”), each position corresponding to a specific peptide sequence and the series then forming a two-dimensional array of peptides.
- spot defined positions
- Different methods for preparing such arrays have recently been described (for a review, see Figeys and Pinto, 2001, Electrophoresis 22: 208-216; Walter et al, 2000, Curr Opin Microbiol 3: 298-302).
- the series of these methods generally include covalently fixing the peptides on a support, in particular using chemical linkers.
- the skilled person could refer to the “SPOT synthesis” technique consisting of directly synthesizing peptides comprising up to 20 residues on a cellulose membrane (Frank and Overwing, Methods in Molecular Biology, 1996, vol 66: 149-169, Epitope Mapping Protocols, edited by: G E Morris, Humana Press Inc, Totowa N.J.).
- any method can be used provided that it can produce an array of peptides deposited on a solid support that can be used to detect specific interactions between the deposited peptides and particular compounds.
- the series of deposited peptide sequences covers the complete sequence of the viral, parasitic or cellular protein from which those sequences are derived.
- the process can test, in a single step, the complete sequence of a given protein, this being “sectioned” into a finite number of peptides with generally overlapping sequences.
- the peptides deposited in the form of a spot are less than 20 amino acids in size, and more preferably are less than 15 amino acids in size.
- the peptides are deposited on a cellulose membrane.
- the array obtained is brought into contact in step b) with a type 2A protein phosphatase holoenzyme or one of its subunits.
- type 2A protein phosphatase holoenzyme means any purified dimeric (AC) or heterotrimeric (ABC) complex of a cellular or reconstituted extract after purifying two subunits (A) and (C) of a type 2A protein phosphatase and if necessary a subunit (B).
- the type 2A protein phosphatases are preferably derived from mammals.
- the supports are incubated, for example, in a buffer solution comprising purified protein phosphatase or one of its purified subunits.
- a suitable buffer solution is TBS (TRIS BORATE) containing 5% of skimmed Regilait (milk) and 3% of BSA.
- the peptide onto which the type 2A protein phosphatase holoenzyrne is bound is generally identified by direct or indirect labeling of the protein phosphatase and identifying the spots to which the labeled protein has bound. Binding of PP2A or one of its subunits to one of the peptide spots can then be revealed, in particular using antiserums, using techniques that are conventionally used for Western Blot or solid phase ELISA test, after incubating the support containing the peptide array with an antibody directed against subunits (A) or (B) or (C) or a mixture of antibodies directed against subunits (A), (B) or (C) of PP2A.
- the method of the invention can be applied to identifying peptides, in particular for use in treating certain viral or parasitic infections, measuring less than 30 amino acids in size or even less than 20 amino acids, said peptides being capable of binding a type 2A protein phosphatase holoenzyme or one of its subunits in vitro.
- the invention provides a natural or synthetic peptide measuring less than 30 amino acids, preferably less than 20 amino acids, characterized in that in vitro, it specifically binds a type 2A protein phosphatase holoenzyme or one of its subunits (A), (B) or (C).
- the term “specifically binds” means that the peptide is capable of competitively inhibiting binding of a protein of viral or parasitic origin with PP2As.
- the peptide of the invention is characterized in that it is a fragment of a viral, parasitic or cellular protein, said protein binding in vitro a type 2A protein phosphatase or one of its subunits, or a sequence that is distinguished from the preceding protein fragment by substitution or deletion of amino acids, said distinct sequence nevertheless conserving the properties of binding to the type 2A protein phosphatase or one of its subunits.
- the number of amino acids substituted or deleted from the distinct sequence compared with the initial sequence does not exceed 20%, more preferably 10% of the amino acids number constituting the initial sequence.
- only amino acids the deletion of which does not affect the in vitro binding properties of the peptide to PP2A are substituted or deleted.
- one distinct sequence is a peptide sequence increasing the binding affinity to type 2A protein phosphatase or one of its subunits compared with the sequence from which it is derived.
- a further distinct sequence as defined above is a peptide sequence homologous with an initially identified peptide sequence.
- the term “homologous peptide” as used in the present invention means a sequence derived from a protein of species other than the initially identified peptide sequence, and for which the primary sequence can be aligned with the peptide sequence initially identified using a conventional optimum alignment program such as the BESTFIT program (Wisconsin Genetics Software Package, Genetics Computer Group, GCG).
- a sequence A will be considered to be homologous with a sequence B if said sequences A and B have at least 50% identity, preferably 75% identity after aligning the sequences using an optimum alignment program such as the BESTFIT program.
- two sequences are also considered to be homologous if the sequences are quasi-identical, with the exception of a few residues that can represent 10% to 20% variability over the whole sequence.
- amino acids with the same chemical function such as Arg and Lys
- the peptides to be analyzed for their binding with a PP2A or one of its subunits are generally selected from fragments of viral, parasitic or cellular proteins, which proteins have been shown to interact in vivo or in vitro with a type 2A protein phosphatase.
- viral parasitic or cellular proteins are selected from one of the following proteins: the t antigen of SV40 or polyoma, the middle t antigen of polyoma, the type B (B, B′, B′′) subunit of PP2A, CK2 ⁇ , CaMIV, p70S6-kinase, Pak1/Pak3, Tap42/alpha 4, PTPA, Set/I1/I2-PP2A, E4orf4, tau, Vpr or CD28, CCXR2 (chemokine receptor).
- a preferred peptide of the invention is a fragment of the CD28 protein, and in particular peptides constituted by the sequences PRRPGPTRKHY (SEQ ID No: 132) and (PRRPGPTRK) 2 (SEQ ID No: 133), respectively corresponding to the peptides termed FD2 and FD3 the intracellular penetration capacity and effects on cell viability of which are described below in the experimental section.
- the present invention also pertains to peptide sequences that are distinguished from the preceding protein by substitution or deletion of amino acids, said distinct sequences nevertheless conserving the properties of binding to type 2A protein phosphatase or one of its subunits.
- a particularly preferred peptide of the invention is a fragment of the Vpr protein of the HIV virus, in particular a fragment of the Vpr protein of the HIV-1 or HIV-2 virus, or a sequence that is distinguished from the preceding protein fragment by substitution or deletion of amino acids, said distinct sequence nevertheless conserving the properties of binding to type 2A protein phosphatase or one of its subunits.
- the invention does not encompass the peptide, a fragment of the Vpr protein having the following sequence: LFIHFRIGCQHSRIGITRRRRVRDGSSRP* disclosed in the EMBL database, accession number P89821.
- using said peptide in the context of the applications described below falls within the scope of the present invention.
- peptides derived from a protein which interacts with type 2A protein phosphatase derived from protamine are the peptide with sequence RRRRRRRSRGRRRRTY (SEQ ID No: 140, termed FD8) or a sequence that is distinguished from SEQ ID No: 140 by substitution or deletion of amino acids, said distinct sequence nevertheless conserving the properties of binding to type 2A protein phosphatase or one of its subunits.
- a peptide of the invention is characterized in that it is included in one of the following sequences:
- a particularly preferred peptide of the invention is a fragment of the peptide SEQ ID No: 2, said fragment consisting of or comprising the peptide with sequence RHSRIG (SEQ ID No: 135), termed FD9, the capacity for intracellular penetration and the effect on cell viability of which are described below in the experimental section.
- the invention also concerns a compound with a polypeptide framework containing a peptide of the invention as defined above, said compound having a molecular weight in the range 10 to 150 Kdaltons and having the capacity to bind protein phosphatase 2A.
- the invention also concerns a polypeptide, characterized in that it is constituted by a repeat of a peptide of the invention.
- polypeptides are the peptide RHSRIG polymers, and in particular the dimer (RHSRIG) 2 (SEQ ID No: 136) or the trimer (RHSRIG) 3 (SEQ ID No: 137), respectively termed FD10 and FD11, the capacity for intracellular penetration and the effect on cell viability of which are described below in the experimental section.
- Peptides with sequences that are distinguished from SEQ ID No: 1 or SEQ ID No: 2 by substitution or deletion of amino acids and falling within the scope of the invention that can in particular be cited peptides the sequence of which is included in one of the sequences for the Vpr protein of different variants of type HIV-1, HIV-2 and SIV, corresponding to homologous sequences in variants of SEQ ID No: 1 or SEQ ID No: 2.
- VEALIRILQQLL SEQ ID No: 6
- ALIRILQQLLFI SEQ ID No: 7
- IRILQQLLFIHF SEQ ID No: 8
- ILQQLLFIHFR SEQ ID No: 9
- RHSRIGIIQQRR SEQ ID No: 10
- SRIGIIQQRRTR SEQ ID No: 11
- IGIIQQRRTRNG SEQ ID No: 12
- a particular sequence of the invention that is distinguished from SEQ ID No: 2 by deletion or substitution of amino acids is the sequence RHSRIGVTRQRRARNG (SEQ ID No: 139), also termed FD13 in the experimental section described below.
- a preferred peptide of the invention is a peptide selected from sequences SEQ ID No: 1 and SEQ ID No: 2 and is characterized in that its administration induces apoptosis of tumour cells.
- One method for selecting peptides that can induce tumour cell apoptosis can be implemented, for example, using the MTT viability test described in the experimental section.
- a further preferred implementation of the invention provides a peptide characterized in that it derives from a fragment of the CK2 ⁇ protein.
- the natural or synthetic peptide is characterized in that it derives from a fragment of the CK2 ⁇ protein of the Theileria parva parasite.
- a peptide of the invention is characterized in that it is included in one of the following sequences:
- sequences from site 1 RKIGRGKFSEVFEG (SEQ ID No: 3), in particular the peptide with the sequence RKIGRGKFSEVF and the peptide with sequence IGRGKFSEVFEG or sequences from site 2 (TVTKDKCVIKILKPVKKKKIKRIKILQNL) (SEQ ID No: 4), in particular the following peptides: TVTKDKCVIKIL; (SEQ ID No: 13) TKDKCVIKLLKP; (SEQ ID No: 14) DKCVIKILKPVK; (SEQ ID No: 15) CVIKILKPVKKK; (SEQ ID No: 16) IKILKPVKKKKI; (SEQ ID No: 17) ILKPVKKKKIKR; (SEQ ID No: 18) KPVKKKKIKREI; (SEQ ID No: 19) VKKKKIKREIKI
- a peptide of the invention comprising a sequence homologous to T parva from site 3 of the CK2 ⁇ protein in P falciparum is the peptide RQKRLI (SEQ ID No: 141).
- the invention also encompasses polymers of the peptide RQKRLI and in particular the trimer (RQKRLI) 3 (SEQ ID No: 134), termed FD7 in the experimental section.
- the invention pertains to a peptide derived from the CK2 ⁇ protein of the parasite Theileria parva, characterized in that its administration reduces parasitic development.
- a further embodiment of the peptides of the invention is characterized in that the peptides are derived from the tau protein.
- the tau sequence has a motif corresponding to the binding site for the E4orf4 adenovirus protein.
- the tau protein is regulated by protein phosphatase 2A. Such peptides should thus be useful in treating Alzheimer's disease.
- the peptides identified by the method of the invention are particularly useful in treating certain tumours and certain viral or parasitic infections.
- the skilled person can select, using binding competition tests, novel peptides derived from the sequences identified using the method of the invention, said peptides competitively inhibiting binding of the native protein from which it derives with a holoenzyme PP2A or one of its subunits.
- the invention also concerns a natural or synthetic peptide as defined above, characterized in that it competitively inhibits interaction of the native protein from which it derives with a PP2A holoenzyme or one of its subunits.
- the peptides of the invention can be coupled to a vector that is capable of transferring said peptide into a eukaryotic cell.
- a vector that is capable of transferring said peptide into a eukaryotic cell.
- the peptides of the invention it is possible, as will be discussed below, for the peptides of the invention to themselves have the capacity to penetrate into cells, meaning that the addition of a vector is not required.
- the invention pertains to means that can synthesise the peptides of the invention.
- the invention pertains to a polynucleotide characterized in that its sequence consists of the sequence coding for a peptide of the invention.
- Preferred polynucleotides are polynucleotides the sequence of which is selected from one of the following sequences: SEQ IDs No: 26 (5′GTGGAAGCCTTAATAAGAATTCTGCAACAACTGCTGTTTATTCATTT CAGAATT); No: 27 (5′CGACATAGCAGAATAGGCATTATTCAACAGAGGAGAACAAGAAATGG A); No: 28 (5′AGGAAGATCGGAAGAGGGAAGTTCAGTGAAGTTTTTGAGGGA); No: 29 (5′ACAGTAACGAAGGATAAATGCGTAATAAAAATCCTAAAGCCTGTAAA GAAGAAGAAAATCAAGAGAGATTAAGATTCTACAGAACCTA); or No: 30 (5′AAAATACTAAGGCTAATTGACTGGGGATTAGCTGA
- the invention also concerns polynucleotides with sequences complementary to one of sequences SEQ ID No: 26-30 and sequences hybridizing under stringent conditions to said polynucleotides.
- stringent conditions means conditions that allow specific hybridization of two single strand DNA sequences at about 65° C., for example in a solution of 6 ⁇ SSC; 0.5% SDS, 5 ⁇ Denhardt's, solution and 100 ⁇ g of non specific carrier DNA or any other solution with an equivalent ionic strength and after washing at 65° C., for example in a solution of at most 0.2 ⁇ SSC and 0.1% SDS or any other solution with an equivalent ionic strength.
- the parameters defining the stringency conditions depend on the temperature at which 50% of the paired strands separate (Tm).
- the stringency conditions have also been defined using protocols described by Sambrook et al, 2001 (Molecular cloning: a laboratory manual, 3 rd edition, Cold Spring Harbor, Laboratory Press, Cold Spring Harbour, N.Y.).
- the invention pertains to a polynucleotide characterized in that it consists of a multimer of a polynucleotide coding for a peptide of the invention.
- the invention also pertains to a polypeptide characterized in that it is constituted by a repeat of a peptide of the invention.
- the invention also pertains to a cell expression vector, characterized in that it comprises a polynucleotide as defined above and regulatory sequences allowing expression of a peptide of the invention in a host cell.
- the invention also pertains to a method for preparing a peptide as defined in the invention, comprising transforming a host cell using a cellular expression vector as defined above, followed by culturing the transformed host cell, and recovering the peptide in the culture medium.
- the invention further pertains to an antiserum or immunoserum or a purified polyclonal antibody or a monoclonal antibody, characterized in that said antibody or said antiserum or immunoserum is capable of specifically binding a peptide in accordance with the invention.
- Antibodies specifically directed against the peptides identified by the process of the invention are obtained, for example, by immunizing an animal after injecting a peptide of the invention, and recovering the antibodies produced.
- a monoclonal antibody can be obtained using techniques that are known to the skilled person, such as the hybridoma method describd by Kohler and Milstein (1975).
- the antibodies obtained are of particular application in immunotherapy.
- they can act as antagonists for viral or parasitic proteins directed against protein phosphatase 2A to block viral or parasitic development.
- polynucleotides encoding the peptides of the invention can be directly transferred to the nucleus of target cells, if necessary using suitable vectors, to allow in vivo expression of the corresponding peptides, said peptides being susceptible of blocking by competitive inhibition a specific interaction between the protein phosphatase 2A and the viral or parasitic protein from which they derive.
- the invention thus pertains to a pharmaceutical composition
- a pharmaceutical composition comprising one of the elements selected from a polynucleotide of the invention or an antibody of the invention.
- the invention also concerns a pharmaceutical composition
- a pharmaceutical composition comprising one of the peptides of the invention in combination with a pharmaceutically acceptable vehicle.
- the invention further concerns the use of a peptide of the invention as defined above in preparing a drug for use in treating a viral or parasitic infection.
- the invention concerns the use of a peptide the sequence of which derives from a fragment of the Vpr protein as defined above, in preparing a drug that can inhibit an HIV infection.
- the peptides of the invention can advantageously be selected so as to stimulate the induction of apoptosis linked to activation of cellular protein phosphatase 2A.
- the invention also concerns the use of a peptide of the invention as defined above in preparing a drug that can induce apoptosis of target cells and in particular tumour cells.
- the invention concerns the use of a peptide the sequence of which derives from a fragment of the CK2 ⁇ protein in preparing a drug that can inhibit parasitic infection. More particularly, the invention concerns the use of a peptide in preparing a drug for use in treating malaria.
- the viral or parasitic infection results in specific expression of proteins comprising sequences of peptides of the invention.
- the sequences encoding the peptides of the invention can thus be used as a probe to detect, in a specific manner from RNA extracted from a biological sample from a patient, a specific viral infection or parasitic infection.
- an antibody of the invention can be used to specifically recognize peptide sequences contained in viral or parasitic proteins expressed during infection.
- the invention concerns the use of a polynucleotide of the invention or an antibody of the invention in the in vitro diagnosis of parasitic or viral diseases.
- the invention also pertains to the selection and use of a peptide binding protein phosphatase 2A, and capable of penetrating into cells.
- peptide FD6 SEQ ID No: 20
- peptide FD6 SEQ ID No: 20
- CK2 ⁇ protein of T parva An example of such a peptide is illustrated by the peptide FD6 (SEQ ID No: 20) derived from the CK2 ⁇ protein of T parva. It has been shown in the present invention that the presence of that peptide in the cell does not affect the viability of cultivated or maintained mammal cells alive.
- the experimental section below illustrates an application of the method for identifying the peptides of the invention to identifying peptides from the Vpr protein of HIV-1 and of the CK2 ⁇ protein from the Theileria parva parasite.
- the invention also pertains to the selection and use of a peptide binding protein phosphatase 2A and possibly capable of penetrating into a cell, said peptide enabling targeting of and contact with intracellular protein phosphatase 2A of a molecule capable of regulating the activity of protein phosphatase 2A.
- FIG. 1 Screening of a membrane containing peptides covering the sequence for Vpr of HIV-1 with the structural subunit A of PP2A (A) and the holoenzyme PP2A1 (B).
- VEALIRILQQLLFIHFRI SEQ ID No: 1
- Peptide 54 VEALLRILQQLL Peptide 55: ALIRILQQLLFI Peptide 56: IRILQQLLFIHF Peptide 57: ILQQLLFIHFRI
- RHSRIGIIQQRRTRNG SEQ ID No: 2
- Peptide 64 RHSRIGIIQQRR Peptide 65: SRIGIIQQRRTR Peptide 66: IGIIQQRRTRNG
- FIG. 2 Screening of a membrane containing peptides covering the sequence for CK2 ⁇ of Theileria with (A) the structural subunit A of PP2A and (B) the holoenzyme PP2A1.
- RKIGRGKFSEVFEG SEQ ID No: 3
- Peptide 66 RKIGRGKFSEVF
- Peptide 67 IGRGKFSEVFEG
- Peptide 74 TVTKDKCVIKIL Peptide 75: TKDKCVIKILKP Peptide 76: DKCVIKILKPVK Peptide 77: CVIKILKPVKKK Peptide 78: IKILKPVKKKKI Peptide 79: ILKPVKKKKIKR Peptide 80: KPVKKKKIKREI Peptide 81: VKKKKIKREIKI Peptide 82: KKKIKREIKILQ Peptide 83: KIKREIKILQNL
- FIG. 3 is a histogram representing the intracellular penetration values obtained using a cell penetration test for the peptides cited in Table 3.
- FIG. 4 illustrates the effects of different peptides on the viability of Hela cells evaluated using a MTT viability test.
- Trimeric PP2A1 protein was purified to homogeneity from pig brain.
- a recombinant structural subunit of PP2A was expressed in E coli and purified using the protocol described by Cohen et al (Cohen P, Alemany S, Hemmings B A, Resink T J, Stralfors P, Tung H Y. Protein phosphatase-1 and protein phosphatase 2A from rabbit skeletal muscle. Methods Enzymol 1988 159, 390-408), or that described by Bosch et al (Bosch M, Cayla X, Van Hoof C, Hemmings B A, Ozon R, Merlevede W, Goris J. the PR55 and PR65 subunits of protein phosphatase 2A from Xenopus laevis. Molecular cloning and developmental regulation of expression. Eur J Biochem 1995, 230, 1037-45).
- Binding peptides derived from CK2 ⁇ proteins (encoded by T parva protozoa) or Vpr protein (encoded by the HIV-1 virus) with PP2A were identified using the “spot peptides” technique described above (Frank and Overwing, 1996, Meth Mol Biol 66, 149-169).
- the method consisted of synthesizing dodecapeptides, in situ on a cellulose membrane, at defined positions wherein the series of the sequence covered the whole sequence of the protein of interest (Vpr or CK2 ⁇ ).
- the peptides of two consecutive spots on the membrane overlap with an overlapped by two amino acids.
- each prepared membrane was first saturated for 1 hour at ambient temperature with TBS containing 5% skimmed Régilait (milk) and 3% BSA then incubated overnight in the same buffer in the presence of 4 ⁇ g/ml of purified protein (subunit A of PP2A or holoenzyme PP2A1).
- purified protein subunit A of PP2A or holoenzyme PP2A1
- the specific interaction of each purified protein (respectively the structural subunit A or the trimeric holoenzyme PP2A1) with a peptide sequence was revealed, as in Western blot, after incubating the membrane with an antibody directed against the structural protein A ( FIGS. 1A and 2A ) and with a mixture of antibodies recognizing the proteins A, B and C of PP2A ( FIGS. 1B and 2B ).
- the membranes were washed 5 times for 15 minutes with a conventional TBST buffer (TBS+TWEEN) used for incubation then incubated a further 1 hour at ambient temperature with a second antibody (coupled with peroxidase). Finally, the membranes were washed 5 times for 15 minutes with the TBST buffer and revealed.
- a conventional TBST buffer TBS+TWEEN
- a second antibody coupled with peroxidase
- Hela line which is derived from a human cervical carcinoma.
- Hela cells (10 4 in 100 1) were seeded into 96-well plates (flat bases) with complete DMEM medium in the presence of 2.5% penicillin/ampicillin and 10% foetal calf serum. After incubating overnight at 37° C., in a CO 2 oven (5%), different dilutions of complexes (biotinylated-avidine peroxidase peptides) were added. After incubating for 4 hours the supernatant was aspirated and the cells were washed 3 times with PBS, trypsinated and taken up for counting in PBS. After counting, the cells were taken up in 300 ⁇ l of lysis buffer.
- Hela cells (10 4 for 100 ⁇ l) were seeded into 96-well plates (flat bases) with complete DMEM medium containing 2.5% penicillin/ampicillin and 10% foetal calf serum. After incubating overnight at 37° C. in a CO 2 oven (5%), the cells were cultivated in the presence of different peptide concentrations. After incubating for 72 h, the medium containing the peptides was aspirated and the MTT at 0.5 mg/ml (diluted in DMEM alone) was added in an amount of 100 per well. Incubation was carried out in the dark at 37° C. for 30 minutes then the MTT was aspirated off and 50 ⁇ l of DMSO was added to all wells.
- FIG. 1B Two peptide sequences containing a binding site for the Vpr of HIV-1 with the protein PP2A1 ( FIG. 1B ; “site 1”) and with the subunit A ( FIG. 1A , “site 1” and “site 2”) were identified.
- Three peptide sequences containing a binding site for CK2 ⁇ of T parva with the protein PP2A1 ( FIG. 2B , “site 3”) and with the structural subunit A were also identified ( FIG. 2A , “site 1”, “site 2” and “site 3”).
- Vpr The exogenic expression or expression due to proviral infection of the Vpr of HIV-1 induces apoptosis in Hela cells, T lymphoid lines and primary lymphocytes (Stewart et al, 1997 J Virol 71: 5579-9).
- Vpr mutants known in the art indicates that the peptides identified by the process of the invention and specifically binding the PP2A protein contain sequences which correlate with those required for the pro-apoptotic effect of Vpr.
- fragments of viral proteins, Vpr and E4orf4, which interact with PP2A and are identified by the process of the invention, could be useful in inducing apoptosis of tumor cells.
- the identified peptides are also naturally used in inhibiting infection by HIV or other related viruses and retroviruses.
- PP2A controls cell proliferation via a novel cascade of phosphorylations involving PI3-kinase, PKC ⁇ (identified as a MAP-kinase-kinase-kinase or MEKK), the MEK protein and the two MAP kinases ERK-1 and ERk-2, and transcription factors NF- ⁇ B and Sp1 (Sontag E, Sontag J M, Garcia A (1997), EMBO J, 16, 5662-5671; Ayllon V, Martinez A, C, Garcia A, Cayla X and Rebollo A (2000), EMBO J 19, 1-10, A Garcia, S Cereghini, E Sontag (2000), J Biol Chem 275, 9385-9389).
- FD12 a 18AA peptide the sequence of which derives from that of the FD11 peptide (R is mutated into A).
- This peptide which is homologous with the glucosamine transferase protein of Chlamydia muridarum, affects the viability of the Hela cell ( FIG. 4C ). This biological effect could be due to an interaction with the plasma membrane.
- Vpr a protein coded by the HIV-1 virus, is involved in maintaining a high viral charge and in establishing pathogenesis linked to HIV.
- the expression of Vpr exogenic or due to proviral HIV-1 infection, induces apoptosis in Hela cells, in T lymphoid lines, in primary lymphocytes and in transformed cells (Stewart et al, J Virol 1997, 71, 5579-9; Stewart et al 1999, PNAS, 96, 12039-12043).
- adenovirus E4orf4 Marcellus et al, J Virol 2000, 74, 7869-7877
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/040,862 US8299213B2 (en) | 2001-07-27 | 2011-03-04 | Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0110139A FR2827866B1 (fr) | 2001-07-27 | 2001-07-27 | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations |
FR01/10139 | 2001-07-27 | ||
PCT/FR2002/002705 WO2003011898A2 (fr) | 2001-07-27 | 2002-07-26 | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/002705 Continuation WO2003011898A2 (fr) | 2001-07-27 | 2002-07-26 | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/040,862 Division US8299213B2 (en) | 2001-07-27 | 2011-03-04 | Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060014930A1 true US20060014930A1 (en) | 2006-01-19 |
Family
ID=8866042
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/763,286 Abandoned US20060014930A1 (en) | 2001-07-27 | 2004-01-26 | Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
US13/040,862 Expired - Fee Related US8299213B2 (en) | 2001-07-27 | 2011-03-04 | Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/040,862 Expired - Fee Related US8299213B2 (en) | 2001-07-27 | 2011-03-04 | Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
Country Status (11)
Country | Link |
---|---|
US (2) | US20060014930A1 (ko) |
EP (1) | EP1530584B1 (ko) |
JP (2) | JP4439261B2 (ko) |
KR (2) | KR100950520B1 (ko) |
CN (1) | CN1630663B (ko) |
AT (1) | ATE440860T1 (ko) |
CA (1) | CA2455403C (ko) |
DE (1) | DE60233532D1 (ko) |
ES (1) | ES2331730T3 (ko) |
FR (1) | FR2827866B1 (ko) |
WO (1) | WO2003011898A2 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070015161A1 (en) * | 2003-09-15 | 2007-01-18 | Cenix Bioscience Gmbh | Use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferative diseases |
WO2007022534A1 (en) * | 2005-08-19 | 2007-02-22 | Propepgen Biostrategies, Inc. | Preparation of a peptide compound (norapro-2002) and its use for the activation of protein phosphatase-2a enzymes |
US20070065410A1 (en) * | 2002-10-16 | 2007-03-22 | Institut Pasteur | Peptides binding the phosphatase 2A protein and polynucleotides encoding same |
US20160257713A1 (en) * | 2011-12-27 | 2016-09-08 | Universite Pierre Et Marie Curie (Paris 6) | Cell-penetrating peptides |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2827866B1 (fr) * | 2001-07-27 | 2004-12-10 | Pasteur Institut | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations |
CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
WO2004011595A2 (fr) * | 2002-07-26 | 2004-02-05 | Institut Pasteur | Vecteurs destines au transfert de molecules d'interet dans des cellules cibles |
FR2850396B1 (fr) * | 2003-01-29 | 2005-05-13 | Pasteur Institut | Vecteurs destines au transfert de molecules d'interet dans des cellules cibles |
WO2005103654A2 (fr) * | 2004-04-09 | 2005-11-03 | Bioalliance Pharma | Methode d’identification de composes actifs sur la replication du virus hiv. |
EP1843734A4 (en) | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
FR2903305B1 (fr) * | 2006-07-07 | 2012-06-01 | Soc Extraction Principes Actif | Utilisation d'extraits vegetaux en tant que principes actifs amincissants |
EP2236603A1 (en) | 2009-03-30 | 2010-10-06 | Universite Pierre Et Marie Curie | Pro-apoptotic peptides |
EP2301956A1 (en) | 2009-09-25 | 2011-03-30 | Institut Pasteur | Methods for prognosticating progression or long term non-progression of a HIV infection or HIV-associated disorders in a patient |
WO2012042038A2 (en) | 2010-09-30 | 2012-04-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9 |
WO2013098339A1 (en) * | 2011-12-27 | 2013-07-04 | Universite Pierre Et Marie Curie (Paris 6) | Anti-tumor adjuvant therapy |
CN103788211B (zh) * | 2012-11-01 | 2017-09-01 | 中国科学院上海药物研究所 | 双功能肽、所述双功能肽与核酸分子形成的复合物以及治疗肿瘤的药物组合物 |
EP2868326A1 (en) | 2013-11-04 | 2015-05-06 | Université Pierre et Marie Curie (Paris 6) | Peptide inhibitors of TEAD/YAP-TAZ interaction |
EP2881472A1 (en) | 2013-12-09 | 2015-06-10 | Université Pierre et Marie Curie (Paris 6) | A method of predicting a response to an anti-tumor treatment |
EP3371212B1 (en) | 2015-11-06 | 2023-10-11 | The Board of Trustees of the University of Illinois | Peptides and method for treatment of cardiac arrest |
US11174322B2 (en) | 2017-07-24 | 2021-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat HCMV related diseases |
CN118146308A (zh) * | 2020-04-30 | 2024-06-07 | 中国科学院分子细胞科学卓越创新中心 | 用于治疗胃癌的环肽及其药物组合物 |
WO2023175022A1 (en) | 2022-03-16 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat infectious diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077826A1 (en) * | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
US7056735B2 (en) * | 2000-09-11 | 2006-06-06 | Institut Pasteur | Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087486A (en) * | 1996-01-29 | 2000-07-11 | The Trustees Of The University Of Pennsylvania | Nucleotide sequences encoding vpr receptor protein |
US6159704A (en) * | 1996-03-29 | 2000-12-12 | Novartis Ag | Phosphatase modulator |
CA2259152C (en) * | 1996-07-05 | 2002-02-12 | Philip E. Branton | Adenovirus e4 proteins for inducing cell death |
EP1196773A1 (en) * | 1999-07-12 | 2002-04-17 | McGILL UNIVERSITY | E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
GB9925853D0 (en) * | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
US6664040B2 (en) * | 2000-05-23 | 2003-12-16 | The Regents Of The University Of California | Compositions and methods for delivery of a molecule into a cell |
FR2827866B1 (fr) * | 2001-07-27 | 2004-12-10 | Pasteur Institut | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations |
-
2001
- 2001-07-27 FR FR0110139A patent/FR2827866B1/fr not_active Expired - Fee Related
-
2002
- 2002-07-26 KR KR1020047001216A patent/KR100950520B1/ko not_active IP Right Cessation
- 2002-07-26 JP JP2003517089A patent/JP4439261B2/ja not_active Expired - Fee Related
- 2002-07-26 DE DE60233532T patent/DE60233532D1/de not_active Expired - Lifetime
- 2002-07-26 AT AT02774847T patent/ATE440860T1/de not_active IP Right Cessation
- 2002-07-26 CA CA2455403A patent/CA2455403C/fr not_active Expired - Fee Related
- 2002-07-26 CN CN02818386XA patent/CN1630663B/zh not_active Expired - Fee Related
- 2002-07-26 WO PCT/FR2002/002705 patent/WO2003011898A2/fr active Application Filing
- 2002-07-26 EP EP02774847A patent/EP1530584B1/fr not_active Expired - Lifetime
- 2002-07-26 ES ES02774847T patent/ES2331730T3/es not_active Expired - Lifetime
- 2002-07-26 KR KR1020097010359A patent/KR20090060462A/ko not_active Application Discontinuation
-
2004
- 2004-01-26 US US10/763,286 patent/US20060014930A1/en not_active Abandoned
-
2008
- 2008-11-10 JP JP2008288017A patent/JP2009112309A/ja active Pending
-
2011
- 2011-03-04 US US13/040,862 patent/US8299213B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056735B2 (en) * | 2000-09-11 | 2006-06-06 | Institut Pasteur | Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) |
US20030077826A1 (en) * | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070065410A1 (en) * | 2002-10-16 | 2007-03-22 | Institut Pasteur | Peptides binding the phosphatase 2A protein and polynucleotides encoding same |
US7498306B2 (en) * | 2002-10-16 | 2009-03-03 | Institut Pasteur | Peptides binding to the phosphatase 2A protein |
US20100009909A1 (en) * | 2002-10-16 | 2010-01-14 | Institut Pasteur | Peptides binding the phosphatase 2a protein |
US20070015161A1 (en) * | 2003-09-15 | 2007-01-18 | Cenix Bioscience Gmbh | Use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferative diseases |
US7648827B2 (en) | 2003-09-15 | 2010-01-19 | Cenix Bioscience Gmbh | Use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferative diseases |
WO2007022534A1 (en) * | 2005-08-19 | 2007-02-22 | Propepgen Biostrategies, Inc. | Preparation of a peptide compound (norapro-2002) and its use for the activation of protein phosphatase-2a enzymes |
US20160257713A1 (en) * | 2011-12-27 | 2016-09-08 | Universite Pierre Et Marie Curie (Paris 6) | Cell-penetrating peptides |
US9644001B2 (en) * | 2011-12-27 | 2017-05-09 | Universite Pierre Et Marie Curie (Paris 6) | Cell-penetrating peptides |
Also Published As
Publication number | Publication date |
---|---|
CN1630663A (zh) | 2005-06-22 |
KR20090060462A (ko) | 2009-06-12 |
EP1530584A2 (fr) | 2005-05-18 |
ES2331730T3 (es) | 2010-01-14 |
CA2455403A1 (fr) | 2003-02-13 |
EP1530584B1 (fr) | 2009-08-26 |
JP2009112309A (ja) | 2009-05-28 |
ATE440860T1 (de) | 2009-09-15 |
KR100950520B1 (ko) | 2010-03-30 |
DE60233532D1 (de) | 2009-10-08 |
WO2003011898A2 (fr) | 2003-02-13 |
JP4439261B2 (ja) | 2010-03-24 |
FR2827866A1 (fr) | 2003-01-31 |
JP2005522185A (ja) | 2005-07-28 |
CA2455403C (fr) | 2012-05-29 |
US20110269674A1 (en) | 2011-11-03 |
WO2003011898A3 (fr) | 2005-03-17 |
US8299213B2 (en) | 2012-10-30 |
KR20040044435A (ko) | 2004-05-28 |
CN1630663B (zh) | 2010-05-12 |
FR2827866B1 (fr) | 2004-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8299213B2 (en) | Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses | |
JP2005522185A5 (ko) | ||
Guy et al. | HIV F/3'orf encodes a phosphorylated GTP-binding protein resembling an oncogene product | |
Timmins et al. | Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4 | |
Polte et al. | Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. | |
Fiorentini et al. | Functions of the HIV-1 matrix protein p17 | |
Srinivas et al. | Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins. | |
US20050233963A1 (en) | Heat shock response and virus replication | |
Sabbah et al. | Interaction between the HIV‐1 protein Vpr and the adenine nucleotide translocator | |
US7642051B2 (en) | Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT) | |
US7541036B2 (en) | Human immunodeficiency virus type 1 (HIV-1) matrix (MA or p17) polypeptide capable of inducing anti-p17 antibodies that neutralize the proinflammatory activities of the MA protein | |
US20160090402A1 (en) | Peptide domain required for interaction between the envelope of a virus pertaining to the herv-w interference group and an hasct receptor | |
US8299031B2 (en) | Human semen enhancer of viral infection peptides (SEVI) and their use | |
US20160193281A1 (en) | Map kinase p38 binding compounds | |
US7498306B2 (en) | Peptides binding to the phosphatase 2A protein | |
Okamoto et al. | HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation | |
WO2004009028A2 (en) | Method and composition for treating and preventing influenza infection and symptoms thereof | |
CN117858897A (zh) | 抗pd-1信号肽抗体及其应用 | |
Oufir et al. | Artificial 64‐residue HIV‐1 enhancer‐binding peptide is a potent inhibitor of viral replication in HIV‐1‐infected cells | |
CA2502411A1 (fr) | Peptides liant la proteine phosphatase 2a et polynucleotides les codant | |
Safe | Vaccination with Cancer-and HIV | |
Sundaram | Evaluation of T-cell and B-cell epitopes and design of multivalent vaccines against HTLV-1 diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INSTITUT PASTEUR, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GARCIA, ALPHONSE;CAYLA, XAVIER;REBOLLO, ANGELITA;AND OTHERS;REEL/FRAME:015594/0142;SIGNING DATES FROM 20040609 TO 20040613 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GARCIA, ALPHONSE;CAYLA, XAVIER;REBOLLO, ANGELITA;AND OTHERS;REEL/FRAME:015594/0142;SIGNING DATES FROM 20040609 TO 20040613 Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CIENIFICAS, SP Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GARCIA, ALPHONSE;CAYLA, XAVIER;REBOLLO, ANGELITA;AND OTHERS;REEL/FRAME:015594/0142;SIGNING DATES FROM 20040609 TO 20040613 Owner name: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, FRA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GARCIA, ALPHONSE;CAYLA, XAVIER;REBOLLO, ANGELITA;AND OTHERS;REEL/FRAME:015594/0142;SIGNING DATES FROM 20040609 TO 20040613 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |